Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Keryx Bio gets review to broaden Auryxia to anemia

Wednesday, March 8, 2017 8:09
% of readers think this story is Fact. Add your two cents.

Keryx biopharmaceuticals Inc (Nasdaq:KERX) has applied to broaden approval for its Auryxia dialysis treatment to include iron deficiency anemia.

US regulator, the Food and Drug Administration, has agreed to review the application, which indicates that the application is sufficiently complete to permit a substantive review.

The target date for the FDA to complete its sNDA review is 6 November, 2017.

Auryxia (ferric nitrate) is currently approved for use in the US for the control of serum phosphorus levels in patients with end-stage renal disease requiring dialysis.

 “Iron deficiency anemia is a common complication in people with non-dialysis dependent chronic kidney disease, yet currently there are no FDA-approved oral medicines to treat this debilitating disease,” said John Neylan, chief medical officer at Keryx.

“Acceptance of the sNDA filing not only brings us one step closer to providing this medicine to patients in need; it is an important milestone for the company and our efforts to leverage ferric citrate’s mechanism of action.”

The sNDA was based on data from a 24-week placebo controlled Phase 3 trial in 234 adults. 

Story by ProactiveInvestors


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global

Top Alternative



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.